Snow Lake Resources Azioni (NASDAQ: LITM)

Ultime notizie per Snow Lake Resources (NASDAQ:LITM) Azioni

Snow Lake Resources

Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.

Wall Street New York Stock Exchange

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

LITM

MERC

Azioni che hanno subito una vendita eccessiva mostrano ora segnali che suggeriscono un&#39;inversione di rotta imminente. Scopri di chi si tratta.

3 titoli ipervenduti pronti al rimbalzo nel prossimo trimestre

Snow Lake Resources Ltd

Litman Gregory Funds Trust IMGP Berkshire Dividend Growth ETF

Litman Gregory Funds Trust Im Rba Responsible Global Allocation ETF

Litman Gregory Funds Trust Polen Capital China Growth ETF

Litman Gregory Funds Trust Polen Capital Emerging Markets ex China Growth ETF

Litman Gregory Funds Trust Polen Capital Global Growth ETF

Litman Gregory Funds Trust Polen Capital International Growth ETF

Litman Gregory Funds Trust iMGP DBi Hedge Strategy ETF

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) with a Outperform and lowers the price target from $14.5 to $14.

Price Target

Analyst Ratings

NMRK

Keefe, Bruyette & Woods Maintains Outperform on Newmark Group, Lowers Price Target to $14

Canaccord Genuity analyst David Hynes maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Buy and lowers the price target from $28 to $26.

ZETA

Canaccord Genuity Maintains Buy on Zeta Global Holdings, Lowers Price Target to $26

Wedbush analyst Yun Zhong maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $181 to $212.

ASND

Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $212

Keefe, Bruyette &amp; Woods analyst Bose George maintains Annaly Capital Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>) with a Outperform and raises the price target from $20.15 to $20.5.

Keefe, Bruyette & Woods Maintains Outperform on Annaly Capital Management, Raises Price Target to $20.5

WIIM

TNMG

TNMG stock has given up its prior loss. TNL Mediagene shares were trading lower after the company reported a year-over-year decrease in FY24 EPS results.

Canaccord Genuity analyst David Hynes maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Buy and lowers the price target from $300 to $255.

TEAM

Canaccord Genuity Maintains Buy on Atlassian, Lowers Price Target to $255

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Outperform and maintains $30 price target.

Reiteration

TVTX

Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $30 Price Target

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Midland States Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSBI#NASDAQ">MSBI</a>) with a Market Perform and lowers the price target from $21 to $20.

MSBI

Keefe, Bruyette & Woods Maintains Market Perform on Midland States Bancorp, Lowers Price Target to $20

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) ("DeFi Dev Corp" or the "Company") announced today that it will begin trading under its new ticker symbol "DFDV" on the Nasdaq Capital Market, effective at market open on May 5, 2025. The change reflects the Company's previously announced corporate name change, deemed market effective by Nasdaq from May 5, 2025, and declared effective as of April 17, 2025 (as previously disclosed), and its strategic shift toward a crypto-forward treasury model anchored in Solana (SOL).
As of May 5, 2025, all Company stock trading, filings, and market related information will be reported under the new symbol "DFDV". The Company's CUSIP number will remain unchanged, and no action is required from shareholders. No other aspects of the Company's corporate structure or operations are impacted by the ticker symbol change.

JNVR

DeFi Development Corp. Announces Ticker Symbol Change To "DFDV", Effective At Market Open On May 5, 2025

Canaccord Genuity analyst Jason Tilchen maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Buy and raises the price target from $80 to $84.

RBLX

Canaccord Genuity Maintains Buy on Roblox, Raises Price Target to $84

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Outperform and raises the price target from $129 to $131.

Keefe, Bruyette & Woods Maintains Outperform on KKR, Raises Price Target to $131

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $394 to $420.

MDGL

Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $420

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 15 years by 5.76% on an annualized basis producing an average annual return of 16.88%. Currently, Blackstone has a market capitalization of $105.69 billion. 
Buying $1000 In BX: If an investor had bought $1000 of BX stock 15 years ago, it would be worth $11,233.77 today based on a price of $136.72 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746200725_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Wedbush analyst Daniel Ives maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and raises the price target from $250 to $270.

AAPL

Wedbush Maintains Outperform on Apple, Raises Price Target to $270

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) with a Outperform and raises the price target from $183 to $189.

Keefe, Bruyette & Woods Maintains Outperform on Intercontinental Exchange, Raises Price Target to $189

Wedbush analyst Scott Devitt downgrades Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Outperform to Neutral and lowers the price target from $150 to $135.

Downgrades

ABNB

Wedbush Downgrades Airbnb to Neutral, Lowers Price Target to $135

Canaccord Genuity analyst William Plovanic maintains iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) with a Buy and lowers the price target from $152 to $139.

IRTC

Canaccord Genuity Maintains Buy on iRhythm Technologies, Lowers Price Target to $139

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains First Commonwealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCF#NYSE">FCF</a>) with a Market Perform and lowers the price target from $19 to $18.

Keefe, Bruyette & Woods Maintains Market Perform on First Commonwealth, Lowers Price Target to $18

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Market Perform and raises the price target from $307 to $315.

Keefe, Bruyette & Woods Maintains Market Perform on Arthur J. Gallagher, Raises Price Target to $315

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $103 to $106.

DXCM

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $106

Press Releases

Snow Lake Exploration Program Underway at Engo Valley Uranium Project

Snow Lake Updates on the Joint Venture with Global Uranium and Enrichment Limited on the Pine Ridge Uranium Project

Snow Lake Phase 2 Drill Program Underway at Engo Valley

Snow Lake Launches Strategic Growth Plan Targeting Investments in Solana Crypto (SOL), and Clean Energy Technologies

Snow Lake and Global Uranium and Enrichment Limited Successfully Close the Acquisition of the Pine Ridge Uranium Project

Pine Ridge Project Significantly Expanded

Snow Lake Announces Reverse Stock Split

Snow Lake to Participate in a Virtual Critical Minerals Conference Presented by Maxim Group LLC on Tuesday, May 6th at 8:30 a.m. EST

American Battery Technology Company - Common Stock

American Battery Tech

BHP Group Limited American Depositary Shares (Each representing two Ordinary Shares)

Comments

Snow Lake Resources

Notizie

Ultime notizie per Snow Lake Resources (NASDAQ:LITM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO